STAT’s Adam Feuerstein said in a series of tweets regarding a short report published earlier today about Ligand by Citron Research: “What I found most disappointing (and fundamentally dishonest) about Andrew’s work is the accusation that $LGND is lying to investors about its royalty-based business model…That’s simply false. There are few pharma companies that disclose more information about their business in a fully transparent manner than $LGND…Now, you may dislike $LGND royalty-based model or believe the company is over-valued. Nothing wrong there. But instead of making the bear case in a strong, fundamental way, @CitronResearch just screams “Fraud” with no substance…That’s sensationalism, not research.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.